Myelodysplastic Syndromes (MDS)
MDS and Agent Orange with Dr. David Steensma
Anna Halpern, MD
Kanwaldeep Mallhi, MD
Azacitidine Improves RBC-TI Rates in Patients with Lower-Risk MDS
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes
Myelodysplastic syndrome/Myeloproliferative neoplasms (MDS/MPNs) are molecularly complex, clinically heterogeneous diseases that exhibit proliferative and dysplastic features. Diagnostic criteria use clinical, pathologic, and genomic features to distinguish between disease entities, though considerable clinical and genetic overlap persists. MDS/MPNs are associated with a poor prognosis, save for MDS/MPN with ring sideroblasts and thrombocytosis, which can behave more indolently.
Venetoclax
Venetoclax Venetoclax: Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults.
Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study
Objectives: Evidence-based guidelines call for integration of palliative care within oncology from diagnosis. Misperceptions about palliative care have impeded implementation. Prior research has not examined perceptions about 'palliative care' versus 'supportive care' among patients and caregivers to whom this care is introduced routinely as part of comprehensive cancer care.